Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: pooled analysis of the SUSTAIN 1-5 trials
Policies are equally clear and easy to find
Research Evidence Comparison# Orforglipron# The ATTAIN program includes ATTAIN-1 (obesity, 12.4% weight loss at 36 mg, 72 weeks, published in NEJM), ATTAIN-2 (obesity + T2D, 10.5% weight loss), and ATTAIN-MAINTAIN (weight maintenance after injectable switch)
doi: 10.3390/biom11121903 216 SimonEClinoiuLFMitreaLVodnarDC
The SSRI, which inhibit serotonin transporter SERT/SLC6A4 (expressed in both neurones and astroglia) and thus increase bioavailability of serotonin, are probably the most widely used in the treatment of depression
39 One of the more important aspects of this disease is the chronic inflammatory and oxidative stresses that accompany the infection, which eventually contribute to the loss of CD4 (helper) T-cells, increased opportunistic infections, immuno-deficiency in general, wasting disease, and death